Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

The FDA has issued a warning as fake Ozempic have started circulating amid a recent trend seeing people using the diabetes ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Dan Haar: Ozempic and Wegovy are expensive. Connecticut wants to make its own cheaper version.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.

He’s also very sensitive about his weight. Is it wrong for me to try to get him to take Ozempic? I’m hoping that losing weight will help boost his energy levels, which might lead to more self ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users.

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and deaths.

In recent years, the dr*g has become so sought after that Ozempic’s manufacturer, Novo Nordisk, has become Europe’s most valuable company, with a market value that exceeds that of its home ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...